NCT00884845View on ClinicalTrials.gov

Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Advanced Malignant Solid Tumors
Interventions
DRUG

PM02734 and erlotinib

PM02734 drug product (DP) 1 mg/vial is a powder for concentrate for solution for infusion

DRUG

Erlotinib

Erlotinib is provided as 25 mg, 100 mg and 150 mg white film-coated tablets

Trial Locations (3)

10467-2490

Montefiore Medical Center, New York

08916

Hospital Universitario Germans Trias i Pujol, Badalona

08020

Intituto Universitario Dexeus, Barcelona

Sponsors

Lead Sponsor

PharmaMar
All Listed Sponsors
lead

PharmaMar

INDUSTRY